Literature DB >> 35419472

Aurora A and Mcl-1: new potential treatment targets in antiestrogen-resistant breast cancer.

Christina W Yde1.   

Abstract

Antiestrogen resistance is a major clinical limitation in treatment of breast cancer. We have recently reported that Aurora A and Mcl-1 (myeloid cell leukemia 1) are potential novel treatment targets in antiestrogen-resistant breast cancer cells and that Aurora A expression is a biomarker for tamoxifen resistance in breast cancer patients. Abbreviations: Bcl-2, B-cell lymphoma 2; EGF, epidermal growth factor; ERα, estrogen receptor α; Mcl-1, myeloid cell leukemia 1; VEGF, vascular endothelial growth factor.
© 2021 Taylor & Francis Group, LLC.

Entities:  

Keywords:  Aurora A; Breast cancer; Mcl-1; antiestrogen resistance; fulvestrant; kinase inhibitors; tamoxifen

Year:  2021        PMID： 35419472      PMCID： PMC8997248          DOI： 10.1080/23723556.2014.998898

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN： 2372-3556


  10 in total

Review 1.  Biological determinants of endocrine resistance in breast cancer.

Authors:  Elizabeth A Musgrove; Robert L Sutherland
Journal:  Nat Rev Cancer       Date:  2009-09       Impact factor: 60.716

2.  A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells.

Authors:  S Thrane; A M Pedersen; M B H Thomsen; T Kirkegaard; B B Rasmussen; A K Duun-Henriksen; A V Lænkholm; M Bak; A E Lykkesfeldt; C W Yde
Journal:  Oncogene       Date:  2014-11-03       Impact factor: 9.867

Review 3.  Mcl-1; the molecular regulation of protein function.

Authors:  Luke W Thomas; Connie Lam; Steven W Edwards
Journal:  FEBS Lett       Date:  2010-06-11       Impact factor: 4.124

4.  Estrogen receptor α is the major driving factor for growth in tamoxifen-resistant breast cancer and supported by HER/ERK signaling.

Authors:  Susan Thrane; Anne E Lykkesfeldt; Mathilde S Larsen; Boe S Sorensen; Christina W Yde
Journal:  Breast Cancer Res Treat       Date:  2013-04-23       Impact factor: 4.872

Review 5.  Endocrine-responsive breast cancer and strategies for combating resistance.

Authors:  Simak Ali; R Charles Coombes
Journal:  Nat Rev Cancer       Date:  2002-02       Impact factor: 60.716

6.  Aurora kinase A outperforms Ki67 as a prognostic marker in ER-positive breast cancer.

Authors:  H R Ali; S-J Dawson; F M Blows; E Provenzano; P D Pharoah; C Caldas
Journal:  Br J Cancer       Date:  2012-04-26       Impact factor: 7.640

7.  Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.

Authors:  C Davies; J Godwin; R Gray; M Clarke; D Cutter; S Darby; P McGale; H C Pan; C Taylor; Y C Wang; M Dowsett; J Ingle; R Peto
Journal:  Lancet       Date:  2011-07-28       Impact factor: 79.321

8.  Differential oestrogen receptor binding is associated with clinical outcome in breast cancer.

Authors:  Caryn S Ross-Innes; Rory Stark; Andrew E Teschendorff; Kelly A Holmes; H Raza Ali; Mark J Dunning; Gordon D Brown; Ondrej Gojis; Ian O Ellis; Andrew R Green; Simak Ali; Suet-Feung Chin; Carlo Palmieri; Carlos Caldas; Jason S Carroll
Journal:  Nature       Date:  2012-01-04       Impact factor: 49.962

Review 9.  The aurora kinases in cell cycle and leukemia.

Authors:  B Goldenson; J D Crispino
Journal:  Oncogene       Date:  2014-03-17       Impact factor: 9.867

10.  Aurora-A is a determinant of tamoxifen sensitivity through phosphorylation of ERα in breast cancer.

Authors:  X Q Zheng; J P Guo; H Yang; M Kanai; L L He; Y Y Li; J M Koomen; S Minton; M Gao; X B Ren; D Coppola; J Q Cheng
Journal:  Oncogene       Date:  2013-10-28       Impact factor: 9.867
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.